Revolutionary new pacemaker now available at HonorHealth
On Tuesday, Nov. 7, 2023, HonorHealth was the first health system in the state to usher in a new era of pacemakers for patients with abnormal or slow heart rhythmsLEARN MORE
New recommendations on all GLP-1 medications before surgery
Please review HonorHealth’s important update to the preoperative protocol regarding withholding GLP-1 agonist medications for our patients taking them for diabetes or for weight loss, in order to avoid perioperativeLEARN MORE
Pioneering new robotic treatment for atrial fibrillation
Atrial fibrillation (Afib) affects over 2.7 million Americans. Until recently, treatment options have been limited. HonorHealth is proud to have an elite cardiovascular program at the forefront of pioneering newLEARN MORE
Two new innovative clinical trials for brain tumor patients
Physicians at HonorHealth are excited to lead the fight against aggressive brain tumors with two new innovative clinical trials. The GESTALT trial is assessing the role of radioactive brachytherapy implantsLEARN MORE
New treatment option for patients with complex PAD
HonorHealth is the first and only healthcare provider in Arizona approved to perform a new percutaneous transmural arterial bypass (PTAB) procedure. PTAB therapy provides a new treatment option for patientsLEARN MORE
2023 Neuroscience Symposium on Oct. 26-27
Registration is now open for the 2023 Neuroscience Institute Symposium! All members of the HonorHealth Medical Staff are invited to attend this two-day event for free because of a generousLEARN MORE
HonorHealth Research Institute participates in first ALS prevention study
When Lou Gehrig played first base for the New York Yankees 100 years ago, he was by any era’s standards a physical specimen, eventually playing in what then was aLEARN MORE
Targeting the glucocorticoid receptor with experimental drug
Erkut Borazanci, MD, explains discoveries surrounding the possibility of targeting the glucocorticoid receptor with experimental drug HonorHealth Research Institute oncologist Erkut Borazanci, MD, describes how a Phase 2 clinical trial forLEARN MORE
Tumor infiltrating lymphocytes used for first time at HonorHealth
Novel therapy initiated in first patient with drug-resistant melanoma skin cancer For the first time, an HonorHealth patient has been treated with tumor infiltrating lymphocytes, or TILs, at HonorHealth ResearchLEARN MORE
HonorHealth Research Institute is Arizona’s first to adopt new radiation protection technology in treatment of heart disease
Clinical trial at HonorHealth Research Institute shows substantial drop in laboratory radiation, with most cases producing undetectable radiation exposure to cardiology staff HonorHealth Research Institute announced today that it isLEARN MORE